September 23, 2025

Biogen Partners with Abdi İbrahim in Türkiye

• Biogen has announced a new strategic partnership with Abdi İbrahim, a leader in the Turkish pharmaceutical industry with a 113-year legacy.
• Partnership aims to further expand access to Biogen’s innovative treatments for patients with neurological and rare diseases in Türkiye.

Istanbul, Türkiye – 18 September 2025 – Biogen Inc. (Nasdaq: BIIB) and Abdi İbrahim today announced a new strategic partnership for the distribution of Biogen medicines for neurological and rare diseases in Türkiye.

The partnership aims to bring together expertise and resources from both companies to further bring innovative treatments for patients in Türkiye.

Nezih Barut, Chairman, Abdi İbrahim, commented: “At Abdi İbrahim, we proudly build on our 113-year legacy of leadership in the Turkish pharmaceutical industry, fueled by our patient-centric approach. As Biogen’s partner in Türkiye, we aim to bring the most advanced and up-to-date solutions to patients in this field. This collaboration will facilitate access to innovative treatments for patients and healthcare professionals in Türkiye, making a positive contribution to the healthcare ecosystem.”

Through this strategic partnership, Biogen and Abdi İbrahim are committed to enhancing patient outcomes and advancing the future of healthcare for people living with neurological and rare diseases in Türkiye.

Fraser Hall, President, Biogen Intercontinental Region, commented: “At Biogen, we are dedicated to transforming the lives of patients through groundbreaking science and innovative treatments. Our partnership with Abdi İbrahim reflects a shared commitment to advancing healthcare and delivering meaningful impact for those facing complex conditions.”